Monday, March 27, 2017 3:45:25 PM
XON to me looks almost more like a mutual fund than a stock, as it's comprised of many very dissimilar companies. It's different from anything I've invested in before, but it's my intention to hold GNVC at least until the time it becomes XON, or they cancel the deal.
For the longest time you could multiply the XON price by .297 and arrive at nearly GNVC's price, normally just a few pennies higher. Recently it seems that even greater value is being given to GNVC, which seems to indicate that their is a growing belief that Novartis will pay at least the $5 million milestone for starting a Phase 2B Trial with the hearing drug in the 36 months after the acquisition by XON, this will equate to a little over $1 per GNVC shareholders at the time of the acquisition.
On occasions I've actually seen GNVC at less than .297 X XON. If I were interested in holding XON, I'd look to buy GNVC when it's priced that way. I believe the odds are at least even that you'll see that Novartis payment, and I believe that long term the hearing drug may prove one of XON's greatest assets.
Gary
Recent PGEN News
- Precigen to Participate in the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:00:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:25:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:19:00 PM
- Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates • PR Newswire (US) • 08/14/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 09:09:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:04:35 PM
- Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th • PR Newswire (US) • 08/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:19:45 PM
- Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock • PR Newswire (US) • 08/08/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/06/2024 08:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Precigen Announces Proposed $30 Million Public Offering of Common Stock • PR Newswire (US) • 08/06/2024 08:04:00 PM
- Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:21:47 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:20:43 PM
- Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch • PR Newswire (US) • 07/23/2024 12:01:00 PM
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response • PR Newswire (US) • 06/03/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:03:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 11:00:45 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/28/2024 08:48:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/28/2024 08:44:39 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM